基金supported by the National Institute on Aging(R03AG064374)the Ohio State University Comprehensive Cancer Center+3 种基金supported by the National Institute on Aging(R01AG059711)supported by the National Institute on Aging(R03AG056439,K76AG064431)the University of California,San Francisco Helen Diller Family Comprehensive Cancer CenterThe Cancer and Aging Research Group also supported this review(R33AG059206).
文摘癌症常见于老年人。初诊为恶性肿瘤的患者的中位年龄为66岁,癌症相关死亡的中位年龄为72岁[1]。老年人是癌症患病率增长最快的人群之一[2]。免疫治疗的发展,尤其是免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)的问世,彻底改变了所有年龄层包括老年人在内的肿瘤患者的常规治疗方案。细胞毒性T淋巴细胞相关抗原4、程序性死亡受体1(programmed death receptor-1,PD-1)及其配体(programmed death-ligand 1,PD-L1)的抑制剂可改善多种肿瘤患者的总生存期(overall survival,OS)[3],且部分患者可获得持续缓解[4]。
